FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895957900> ?p ?o ?g. }

• W2895957900 endingPage "82" @default.
• W2895957900 startingPage "75" @default.
• W2895957900 abstract "Objectives To investigate the role of tumor growth velocity in defining tumor progression in metastatic renal cell carcinoma patients treated with the vascular endothelial growth factor tyrosine kinase inhibitor, sorafenib. Methods A modified calculation for tumor growth velocity was introduced to evaluate the tumor growth velocity, before and after sorafenib withdrawal. Known prognostic factors together with tumor growth velocity before drug withdrawal and tumor growth velocity after drug withdrawal were compared using a χ 2 ‐test from a contingency table, and partial likelihood test from a Cox regression model for overall survival. Results A total of 114 patients who reached progressive disease and withdrew from sorafenib were enrolled after a median follow‐up period of 107.8 months. Tumor growth velocity before drug withdrawal was 7.347 ± 4.040, and tumor growth velocity after drug withdrawal was 11.647 ± 5.937 ( P < 0.001). Higher tumor growth velocity before drug withdrawal was correlated with a higher risk Memorial Sloan Kettering Cancer Center score ( P = 0.022), Karnofsky Performance Status <80 ( P = 0.028), non‐clear cell carcinoma ( P = 0.037), higher tumor nucleus grade ( P < 0.001) and best treatment response ( P < 0.001). Patients with tumor growth velocity before drug withdrawal >5.0 had shorter overall survival ( P < 0.001). On multivariate analysis, factors associated with overall survival were high/intermediate Memorial Sloan Kettering Cancer Center risk score (hazard ratio 2.119, P = 0.006), non‐clear histological subtype (hazard ratio 1.900, P = 0.031), tumor growth velocity before drug withdrawal ≥5.0 (hazard ratio 2.758, P < 0.001) and progressive disease as best response (hazard ratio 2.069, P = 0.001). Conclusions Significantly faster tumor growth can be observed if sorafenib is discontinued in the case of disease progression. Thus, we suggest not to withdraw targeted agents until tumor growth velocity is >5.0." @default.
• W2895957900 created "2018-10-26" @default.
• W2895957900 creator A5007183896 @default.
• W2895957900 creator A5014398628 @default.
• W2895957900 creator A5032076802 @default.
• W2895957900 creator A5053347862 @default.
• W2895957900 creator A5058723379 @default.
• W2895957900 creator A5082673411 @default.
• W2895957900 creator A5090976010 @default.
• W2895957900 date "2018-10-16" @default.
• W2895957900 modified "2023-09-25" @default.
• W2895957900 title "Tumor growth velocity: A modified tumor growth rate defining tumor progression during sorafenib treatment in patients with metastatic renal cell carcinoma" @default.
• W2895957900 cites W1970322471 @default.
• W2895957900 cites W1973946393 @default.
• W2895957900 cites W2001973625 @default.
• W2895957900 cites W2026894173 @default.
• W2895957900 cites W2053874226 @default.
• W2895957900 cites W2056665205 @default.
• W2895957900 cites W2059426108 @default.
• W2895957900 cites W2066604995 @default.
• W2895957900 cites W2082982970 @default.
• W2895957900 cites W2086735022 @default.
• W2895957900 cites W2100158834 @default.
• W2895957900 cites W2100163738 @default.
• W2895957900 cites W2101277591 @default.
• W2895957900 cites W2105746319 @default.
• W2895957900 cites W2107907914 @default.
• W2895957900 cites W2110466017 @default.
• W2895957900 cites W2110697333 @default.
• W2895957900 cites W2117687280 @default.
• W2895957900 cites W2123534406 @default.
• W2895957900 cites W2128208856 @default.
• W2895957900 cites W2130048860 @default.
• W2895957900 cites W2132565257 @default.
• W2895957900 cites W2139248078 @default.
• W2895957900 cites W2149569497 @default.
• W2895957900 cites W2161817637 @default.
• W2895957900 cites W2161828857 @default.
• W2895957900 cites W2166802330 @default.
• W2895957900 cites W2546862895 @default.
• W2895957900 cites W2623804585 @default.
• W2895957900 doi "https://doi.org/10.1111/iju.13807" @default.
• W2895957900 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30325072" @default.
• W2895957900 hasPublicationYear "2018" @default.
• W2895957900 type Work @default.
• W2895957900 sameAs 2895957900 @default.
• W2895957900 citedByCount "3" @default.
• W2895957900 countsByYear W28959579002019 @default.
• W2895957900 countsByYear W28959579002020 @default.
• W2895957900 crossrefType "journal-article" @default.
• W2895957900 hasAuthorship W2895957900A5007183896 @default.
• W2895957900 hasAuthorship W2895957900A5014398628 @default.
• W2895957900 hasAuthorship W2895957900A5032076802 @default.
• W2895957900 hasAuthorship W2895957900A5053347862 @default.
• W2895957900 hasAuthorship W2895957900A5058723379 @default.
• W2895957900 hasAuthorship W2895957900A5082673411 @default.
• W2895957900 hasAuthorship W2895957900A5090976010 @default.
• W2895957900 hasBestOaLocation W28959579001 @default.
• W2895957900 hasConcept C121608353 @default.
• W2895957900 hasConcept C126322002 @default.
• W2895957900 hasConcept C143998085 @default.
• W2895957900 hasConcept C207103383 @default.
• W2895957900 hasConcept C2777472916 @default.
• W2895957900 hasConcept C2777546739 @default.
• W2895957900 hasConcept C2778019345 @default.
• W2895957900 hasConcept C2778695046 @default.
• W2895957900 hasConcept C2779256057 @default.
• W2895957900 hasConcept C44249647 @default.
• W2895957900 hasConcept C50382708 @default.
• W2895957900 hasConcept C71924100 @default.
• W2895957900 hasConceptScore W2895957900C121608353 @default.
• W2895957900 hasConceptScore W2895957900C126322002 @default.
• W2895957900 hasConceptScore W2895957900C143998085 @default.
• W2895957900 hasConceptScore W2895957900C207103383 @default.
• W2895957900 hasConceptScore W2895957900C2777472916 @default.
• W2895957900 hasConceptScore W2895957900C2777546739 @default.
• W2895957900 hasConceptScore W2895957900C2778019345 @default.
• W2895957900 hasConceptScore W2895957900C2778695046 @default.
• W2895957900 hasConceptScore W2895957900C2779256057 @default.
• W2895957900 hasConceptScore W2895957900C44249647 @default.
• W2895957900 hasConceptScore W2895957900C50382708 @default.
• W2895957900 hasConceptScore W2895957900C71924100 @default.
• W2895957900 hasFunder F4320321001 @default.
• W2895957900 hasIssue "1" @default.
• W2895957900 hasLocation W28959579001 @default.
• W2895957900 hasLocation W28959579002 @default.
• W2895957900 hasOpenAccess W2895957900 @default.
• W2895957900 hasPrimaryLocation W28959579001 @default.
• W2895957900 hasRelatedWork W1992278374 @default.
• W2895957900 hasRelatedWork W1999193852 @default.
• W2895957900 hasRelatedWork W2082648967 @default.
• W2895957900 hasRelatedWork W2754556903 @default.
• W2895957900 hasRelatedWork W2957827266 @default.
• W2895957900 hasRelatedWork W3005075760 @default.
• W2895957900 hasRelatedWork W4232617294 @default.
• W2895957900 hasRelatedWork W4323536446 @default.
• W2895957900 hasRelatedWork W4379336131 @default.
• W2895957900 hasRelatedWork W4386765885 @default.

• next